This article is more than 5 years old. Information may no longer be current.

VIDEO: Gene therapy for wet AMD ‘on the horizon’

BySzilárd Kiss, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — In the OPTIC trial, patients with wet age-related macular degeneration who were treated with ADVM-022, an intravitreal gene therapy, did not require additional injections following treatment, according to a presenter at the American Academy of Ophthalmology annual meeting.

“A one and done gene therapy treatment is thus on the horizon and the potential for patients to not get those injections or not need those injections is definitely possible,” Szilard Kiss, MD, director of the Retina Service at Weill Cornell Medical Center, told Ocular Surgery News. – by Alaina Tedesco

Reference: Kiss S. 24-week results of phase 1 study of intravitreal gene therapy with ADVM-022 for neovascular AMD (OPTIC Trial). Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Kiss reports being a consultant for Adverum, RegenxBio and Spark Therapeutics.